24 May 2013
Keywords: arqule, updates, early-stage, pipeline, usa-based, updated, investors
Article | 12 January 2009
USA-based ArQule has updated investors on the status of two products in its early-stage product pipeline: ARQ 621, a selective inhibitor ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 January 2009
23 May 2013
© 2013 thepharmaletter.com